[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure]

A Buchwald1, C Unterberg, R van der Does

  • 1Abteilung Kardiologie und Pulmonologie, Universitätsklinik Göttingen.

Zeitschrift Fur Kardiologie
|June 1, 1990
PubMed

Insights

Intravenous carvedilol did not show an acute vasodilating effect in heart failure patients. The drug did not decrease blood pressure or peripheral resistance, contrary to expectations for vasodilation.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Carvedilol, a beta-blocker, is known to induce vasodilation in coronary artery disease patients.
  • Heart failure is often associated with altered hemodynamics and reduced cardiac function.

Purpose of the Study:

  • To investigate the acute vasodilating effect of intravenous carvedilol in patients with heart failure.
  • To assess the impact of carvedilol on hemodynamic parameters during exercise in heart failure.

Main Methods:

  • A double-blind, randomized, placebo-controlled, cross-over study.
  • Inclusion of patients with coronary artery disease and dilated cardiomyopathy (ejection fraction < 40%).
  • Measurement of rate-pressure-product, heart rate, blood pressure, and total peripheral resistance via Swan-Ganz catheterization and supine ergometry.

Main Results:

  • Intravenous carvedilol (5 mg) did not significantly alter blood pressure compared to placebo.
  • Heart rate was lower at rest and during exercise with carvedilol.
  • Total peripheral resistance during exercise was higher with carvedilol, particularly in the coronary artery disease group.

Conclusions:

  • Acute intravenous administration of carvedilol does not demonstrate a vasodilating effect in patients with heart failure.
  • The observed effects on heart rate and peripheral resistance suggest a different hemodynamic profile than anticipated vasodilation.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...